New CEO to drive innovation and growth

Ingenza, a technology-driven CRDMO, has appointed Nick Challoner as Chief Executive Officer, effective 1 October 2025. Challoner brings more than 30 years of international experience across the chemical and biotechnology sectors, with a proven track record in innovation, commercial strategy, and operational leadership.

Most recently Group Chief Scientific Officer at Croda International Plc, Challoner led global R&D strategy, built a biotechnology programme from the ground up, and oversaw the scale-up and regulatory approval of mRNA delivery components used by Pfizer/BioNTech for the Comirnaty COVID-19 vaccine, generating $300 million in sales. His expertise spans multi-organism strain engineering, biocatalysis, downstream processing, and establishing external innovation partnerships.

Challoner succeeds Ingenza founder Ian Fotheringham, who will become President, focusing on advancing the company’s technology strategy, mentoring senior staff, and driving business development.

Executive Chair Ian Shott said: "Nick’s unique combination of strategic vision, scientific insight, and commercial experience makes him the ideal leader for Ingenza as we enter this pivotal growth phase."

Challoner added: "I am honoured to lead Ingenza at such an exciting time. My focus will be on strengthening our position as a leading CRDMO partner, driving innovation and operational excellence, and supporting our talented team to deliver even greater value for our customers."

Fotheringham commented: "With Nick joining as CEO, Ingenza is well-positioned to accelerate growth and innovation, while I concentrate on the technology and strategic pillars of the business."

More information online